Overview, prevention and management of chemotherapy extravasation
- PMID: 26862492
- PMCID: PMC4734939
- DOI: 10.5306/wjco.v7.i1.87
Overview, prevention and management of chemotherapy extravasation
Abstract
Chemotherapy extravasation remains an accidental complication of chemotherapy administration and may result in serious damage to patients. We review in this article the clinical aspects of chemotherapy extravasation and latest advances in definitions, classification, prevention, management and guidelines. We review the grading of extravasation and tissue damage according to various chemotherapeutic drugs and present an update on treatment and new antidotes including dexrazoxane for anthracyclines extravasation. We highlight the importance of education and training of the oncology team for prevention and prompt pharmacological and non-pharmacological management and stress the availability of new antidotes like dexrazoxane wherever anthracyclines are being infused.
Keywords: Antidote; Chemotherapy; Dexrazoxane; Dimethyl sulfoxide; Extravasation; Hyaluronidase; Tissue damage; Vesicant.
References
-
- Coyle CE, Griffie J, Czaplewski LM. Eliminating extravasation events: a multidisciplinary approach. J Infus Nurs. 2014;37:157–164. - PubMed
-
- Hadaway L. Infiltration and extravasation. Am J Nurs. 2007;107:64–72. - PubMed
-
- Cassagnol M, McBride A. Management of Chemotherapy Extravasations. US Pharm, 2009: 3-11
-
- El-Saghir N, Otrock Z, Mufarrij A, Abou-Mourad Y, Salem Z, Shamseddine A, Abbas J. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol. 2004;5:320–321. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources